Prochlorperazine edisylate

To control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation.

• NOTE ON INJECTION: For intramuscular administration, inject deeply into the upper, outer quadrant of the buttock
• Subcutaneous administration is not advisable because of local irritation
• Stability This solution should be protected from light
• Slight yellowish discoloration will not alter potency
• If markedly discolored, solution should be discarded
• Compatibility It is recommended that Prochlorperazine Edisylate Injection not be mixed with other agents in the syringe
• Adults (For children's dosage and administration, see below.) Dosage should be increased more gradually in debilitated or emaciated patients
• ELDERLY PATIENTS In general, dosages in the lower range are sufficient for most
• Elderly patients
• Since they appear to be more susceptible to hypotension and neuromuscular reactions, such patients should be observed closely
• Dosage should be tailored to the individual, response carefully monitored, and dosage adjusted accordingly
• Dosage should be increased more gradually in elderly patients
• TO CONTROL SEVERE NAUSEA AND VOMITING Adjust dosage to the response of the individual
• Begin with lowest recommended dosage

• Do not use in patients with known hypersensitivity to phenothiazines
• Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.)
• Do not use
• In pediatric surgery
• Do not use
• In pediatric patients under 2 years of age or under 20 lbs
• Do not use in children for conditions for which dosage has not been established

Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Prochlorperazine Edisylate Injection, USP is not approved for the treatment of patients with dementia-related psychosis (see BOXED WARNING ). The extrapyramidal symptoms which can occur secondary to prochlorperazine may be confused with the central nervous system signs of an undiagnosed primary disease responsible for the vomiting, e.g., Reye's syndrome or other encephalopathy. …

Drowsiness, dizziness, amenorrhea, blurred vision, skin reactions and hypotension may occur. Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs (see WARNINGS ). Cholestatic jaundice has occurred. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment. There have been a few observations of fatty changes in the livers of patients who have died while receiving the drug. No causal relationship has been established. Leukopenia and agranulocytosis have occurred. Warn patients to report the sudden appearance of sore throat or other signs of infection. …

(See also ADVERSE REACTIONS .) Symptoms Primarily involvement of the extrapyramidal mechanism producing some of the dystonic reactions described above. Symptoms of central nervous system depression to the point of somnolence or coma. Agitation and restlessness may also occur. Other possible manifestations include convulsions, EKG changes and cardiac arrhythmias, fever, and autonomic reactions such as hypotension, dry mouth and ileus. Treatment It is important to determine other medications taken by the patient since multiple drug therapy is common in overdosage situations. …

تناولها عندما تتذكر، إلا إذا اقترب موعد الجرعة التالية. عندها تخطَّ الجرعة المنسية. لا تتناول جرعتين معًا أبدًا للتعويض. راجع النشرة، فبعض الأدوية مختلفة.